EUVIMEDEUVIMED entdecken
Crossref

Is Actinium Really Happening?

Richard Zimmermann

Journal of Nuclear Medicine · 2023-10 · 64 (10) · 1516-1518

DOI: 10.2967/jnumed.123.265907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 17.08.2023. Verfasst von Richard Zimmermann. Beteiligte Einrichtung: Chrysalium Consulting, Lalaye, France; MEDraysintell, Louvain-la-Neuve, Belgium; and Oncidium Foundation, Mont-Saint-Guibert, Belgium richard.zimmerm…. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The most recent survey ([1][1]) related to α-radiotherapy development showed that 27 molecules labeled with 225Ac are presently under development, among which 13 have already reached human test level. The first 225Ac-labeled molecule has entered the clinical phase III stage ([2][2]) and might reach

Autor:innen und Institutionen

  • Chrysalium Consulting, Lalaye, France; MEDraysintell, Louvain-la-Neuve, Belgium; and Oncidium Foundation, Mont-Saint-Guibert, Belgium richard.zimmermann@chrysalium.com.

Zitieren

APA

Zimmermann, R. (2023). Is Actinium Really Happening?. Journal of Nuclear Medicine, 64(10), 1516-1518. https://doi.org/10.2967/jnumed.123.265907

Vancouver

Zimmermann R. Is Actinium Really Happening?. Journal of Nuclear Medicine. 2023;64(10):1516-1518. doi:10.2967/jnumed.123.265907

BibTeX
@article{Zimmermann2023,
  author = {Zimmermann, Richard},
  title = {Is Actinium Really Happening?},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {10},
  pages = {1516--1518},
  doi = {10.2967/jnumed.123.265907}
}
Kostenlos starten →